Cancer surgery among patients older than 65 years is complex with high morbidity underscoring the need for specialized care at high-quality hospitals.
The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...
In Gaza, a patient’s suffering does not end at diagnosis. The Israeli blockade has turned obtaining any medical supplies into ...
Mitchell, who has served as a councilman for 23 years, was diagnosed with bladder cancer in February after previously being ...
Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders ...
Welltica+ on MSN
Tiny implant eliminates bladder cancer in 82% of patients
A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...
The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...
The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show ...
A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...
Ahead of the season, one of the main topics of conversation surrounding the Colorado Buffaloes was coach Deion Sanders’ health. Sanders was away from the team f ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback